J&J Unit Strikes $3.7B Hepatitis B Gene Therapy Deal
By Matthew Guarnaccia ( October 4, 2018, 12:38 PM EDT) -- Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. on Thursday struck a deal with Arrowhead Pharmaceuticals Inc. worth as much as $3.7 billion to help develop and commercialize a gene therapy candidate that may serve as a treatment for chronic hepatitis B....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.